Ayala Pharmaceuticals, Inc. (ADXS) |
| 0.21 0 (0%) 01-13 16:00 |
| Open: | 0.21 |
| High: | 0.21 |
| Low: | 0.0846 |
| Volume: | 10,014 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.03 |
| Exchange: | Other OTC |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.35 |
| Resistance 1: | 1.08 |
| Pivot price: | 0.91 |
| Support 1: | 0.65 |
| Support 2: | 0.54 |
| 52w High: | 0.801 |
| 52w Low: | 0.0011 |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Financials
| EPS | -37340000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -42.915 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -5.00 |
| Return on Assets (ttm) | 419.5 |
| Return on Equity (ttm) | -95.9 |
Company news
Wed, 07 Jan 2026
Ayala Pharmaceuticals (NASDAQ:ADXS) Trading Up 153.7% – Should You Buy? - Defense World
Wed, 09 Apr 2025
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Business Wire
Wed, 29 Jan 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
Thu, 09 May 2024
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - Yahoo Finance
Tue, 20 Feb 2024
Press Telegram - FinancialContent
Thu, 19 Oct 2023
Ayala Pharmaceuticals Announces Closing of Merger with Biosight - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
